Correlation between vitamin D and alterations in MRI among patients with multiple sclerosis
Ann Agric Environ Med. 2021 Sep 16;28(3):372-377. doi: 10.26444/aaem/127062. Epub 2020 Sep 17.ABSTRACTINTRODUCTION: Multiple sclerosis (MS) is a disease of unknown etiology. Diagnosis of MS is primarily based on detection of myelin damage by magnetic resonance imaging (MRI) and classification of demyelination according to the McDonald Criteria. Cholecalciferol (vitamin D3) has been shown to affect the onset and progression of MS via its immunomodulating properties. The role of vitamin D in MS pathogenesis and treatment deserves further investigation, as there is sufficient evidence to suggest a correlation between vitamin ...
Source: Annals of Agricultural and Environmental Medicine : AAEM - September 24, 2021 Category: Environmental Health Authors: Faustyna Pi ędel Agata Rocka Miko łaj Piwek Patryk Piotr Jasielski V éronique Petit Konrad Rejdak Source Type: research
Correlation between vitamin D and alterations in MRI among patients with multiple sclerosis
Ann Agric Environ Med. 2021 Sep 16;28(3):372-377. doi: 10.26444/aaem/127062. Epub 2020 Sep 17.ABSTRACTINTRODUCTION: Multiple sclerosis (MS) is a disease of unknown etiology. Diagnosis of MS is primarily based on detection of myelin damage by magnetic resonance imaging (MRI) and classification of demyelination according to the McDonald Criteria. Cholecalciferol (vitamin D3) has been shown to affect the onset and progression of MS via its immunomodulating properties. The role of vitamin D in MS pathogenesis and treatment deserves further investigation, as there is sufficient evidence to suggest a correlation between vitamin ...
Source: Annals of Agricultural and Environmental Medicine : AAEM - September 24, 2021 Category: Environmental Health Authors: Faustyna Pi ędel Agata Rocka Miko łaj Piwek Patryk Piotr Jasielski V éronique Petit Konrad Rejdak Source Type: research
Correlation between vitamin D and alterations in MRI among patients with multiple sclerosis
Ann Agric Environ Med. 2021 Sep 16;28(3):372-377. doi: 10.26444/aaem/127062. Epub 2020 Sep 17.ABSTRACTINTRODUCTION: Multiple sclerosis (MS) is a disease of unknown etiology. Diagnosis of MS is primarily based on detection of myelin damage by magnetic resonance imaging (MRI) and classification of demyelination according to the McDonald Criteria. Cholecalciferol (vitamin D3) has been shown to affect the onset and progression of MS via its immunomodulating properties. The role of vitamin D in MS pathogenesis and treatment deserves further investigation, as there is sufficient evidence to suggest a correlation between vitamin ...
Source: Annals of Agricultural and Environmental Medicine : AAEM - September 24, 2021 Category: Environmental Health Authors: Faustyna Pi ędel Agata Rocka Miko łaj Piwek Patryk Piotr Jasielski V éronique Petit Konrad Rejdak Source Type: research
Pharmacodynamic biomarkers of long-term interferon beta-1a therapy in REFLEX and REFLEXION
This post-hoc analysis evaluated candidate biomarkers of long-term efficacy of subcutaneous interferon beta-1a (sc IFN β-1a) in REFLEX/REFLEXION studies of clinically isolated syndrome. Samples from 507 REFLEX and 287 REFLEXION study participants were analyzed. All investigated biomarkers were significantly upregulated 1.5–4-fold in response to sc IFN β-1a treatment versus baseline (p ≤ 0.008). The validit y of MX1, 2’5’OAS, and IL-1RA as biomarkers of response to sc IFN β-1a was confirmed in this large patient cohort, with biomarkers consistently upregulated in a dose-dependent manner. (Source: Journal of Neuroimmunology)
Source: Journal of Neuroimmunology - September 8, 2021 Category: Allergy & Immunology Authors: Mark S. Freedman, J érôme Wojcik, Kristina H. Holmberg, Markus Fluck, Mauro D'Antonio, Yann Hyvert, Sofia Stinchi, Vittorio D'Urso, Fernando Dangond Source Type: research
COVID-19 presenting as right flank pain in a postpartum woman: A case report
CONCLUSION: COVID-19 should be in the differential diagnosis of any patient presenting to ED with relevant complaints. Correct and immediate diagnosis is critical for proper treatment and isolation of patients with COVID-19.PMID:34484735 | PMC:PMC8405448 | DOI:10.1016/j.amsu.2021.102770 (Source: Annals of Medicine)
Source: Annals of Medicine - September 6, 2021 Category: Internal Medicine Authors: Venus Chegini Reihaneh Hosseini Neda Zarei Victoria Chegini Faezeh Aghajani Amin Nakhostin-Ansari Sara Kasraei Source Type: research
The Potential Cost-Effectiveness of a Cell-Based Bioelectronic Implantable Device Delivering Interferon- β1a Therapy Versus Injectable Interferon-β1a Treatment in Relapsing–Remitting Multiple Sclerosis
ConclusionInnovative technology such as the Optoferon implant may be a cost-effective therapy for patients with MS. The novel implantable mode of therapeutic protein administration has the potential to become a new mode of treatment administration for MS patients and in other disease areas. However, trials are needed to establish safety and effectiveness. (Source: PharmacoEconomics)
Source: PharmacoEconomics - September 4, 2021 Category: Health Management Source Type: research
Impact of Disease-Modifying Treatments of Multiple Sclerosis on Anti-SARS-CoV-2 Antibodies: An Observational Study
Conclusions
Humoral response after COVID-19 was lower in patients with MS with fingolimod or anti-CD20 mAb. These patients could therefore be at risk of recurrent infection and could benefit from anti–SARS-CoV-2 vaccination. The humoral response after vaccination and the delay before vaccination need to be evaluated.
Classification of Evidence
This study provides Class IV evidence that patients treated with fingolimod or anti-CD20 monoclonal antibodies for MS have a lower humoral response after COVID-19 compared with patients without DMTs or with another DMTs. (Source: Neurology Neuroimmunology and Neuroinflammation)
Source: Neurology Neuroimmunology and Neuroinflammation - July 28, 2021 Category: Neurology Authors: Bigaut, K., Kremer, L., Fabacher, T., Lanotte, L., Fleury, M.-C., Collongues, N., de Seze, J. Tags: COVID-19, Multiple sclerosis Article Source Type: research
Effectiveness, Healthcare Resource Utilization and Adherence to Subcutaneous Interferon Beta-1a According to Age in Patients With Multiple Sclerosis: A Cohort Study Using a US Claims Database
Conclusion: The effectiveness of sc IFN β-1a does not appear reduced as a consequence of age in this real-world setting. Older patients had lower discontinuation rates and reduced disease activity, reflected in lower relapse rates and fewer MRI scans compared with younger patients. (Source: Frontiers in Neurology)
Source: Frontiers in Neurology - July 22, 2021 Category: Neurology Source Type: research
Complex analysis of the personalized pharmacotherapy in the management of COVID-19 patients and suggestions for applications of predictive, preventive, and personalized medicine attitude
ConclusionWe recommend that particularly for patients with comorbidities to avoid serious DDIs, the predictive, preventive, and personalized medicine (PPPM, 3 PM) strategies have to be applied for COVID-19 treatment, and genetic tests should be performed for drugs with actionable pharmacogenes, especially in some ethnic g roups with a higher frequency of functional variations, as our analysis showed. We also suggest that drugs associated with higher ethnic genetic differences should be given priority in future pharmacogenetic studies for COVID-19 management. To facilitate translation of our results into clinical prac ...
Source: EPMA Journal - July 16, 2021 Category: International Medicine & Public Health Source Type: research
Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex)
AbstractRecombinant interferon (IFN) β-1b was approved by the US Food and Drug Administration as the first disease-modifying therapy (DMT) for multiple sclerosis (MS) in 1993. Since that time, clinical trials and real-world observational studies have demonstrated the effectiveness of IFN therapies. The pivotal intramuscular IFN β- 1a phase III trial published in 1996 was the first to demonstrate that a DMT could reduce accumulation of sustained disability in MS. Patient adherence to treatment is higher with intramuscular IFN β-1a, given once weekly, than with subcutaneous formulations requiring multiple injections p...
Source: CNS Drugs - July 6, 2021 Category: Neurology Source Type: research
An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a in severe COVID-19: The COVIFERON II randomized controlled trial
CONCLUSION: The use of high-dose IFN-β 1a did not improve TTCI in hospitalized patients with moderate to severe COVID-19. Also, it did not have any significant effect on mortality reduction compared with treating with low-dose IFN-β 1a.TRIAL REGISTRATION: This trial has been registered as ClinicalTrials.gov, NCT04521400.PMID:34224994 | DOI:10.1016/j.intimp.2021.107916 (Source: International Immunopharmacology)
Source: International Immunopharmacology - July 5, 2021 Category: Allergy & Immunology Authors: Ilad Alavi Darazam Firouze Hatami Mohammad Mahdi Rabiei Mohamad Amin Pourhoseingholi Minoosh Shabani Shervin Shokouhi Masoud Mardani Omid Moradi Farid Javandoust Gharehbagh Nasrinsadat Mirtalaee Halimeh Negahban Mahdi Amirdosara Masoud Zangi Mohammadreza Source Type: research
An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a in severe COVID-19: The COVIFERON II randomized controlled trial
CONCLUSION: The use of high-dose IFN-β 1a did not improve TTCI in hospitalized patients with moderate to severe COVID-19. Also, it did not have any significant effect on mortality reduction compared with treating with low-dose IFN-β 1a.TRIAL REGISTRATION: This trial has been registered as ClinicalTrials.gov, NCT04521400.PMID:34224994 | PMC:PMC8238656 | DOI:10.1016/j.intimp.2021.107916 (Source: International Immunopharmacology)
Source: International Immunopharmacology - July 5, 2021 Category: Allergy & Immunology Authors: Ilad Alavi Darazam Firouze Hatami Mohammad Mahdi Rabiei Mohamad Amin Pourhoseingholi Minoosh Shabani Shervin Shokouhi Masoud Mardani Omid Moradi Farid Javandoust Gharehbagh Nasrinsadat Mirtalaee Halimeh Negahban Mahdi Amirdosara Masoud Zangi Mohammadreza Source Type: research
Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies
ConclusionCDI achievement at any point during the CARE-MS studies was associated with improved disability at year 9, highlighting the potential of alemtuzumab to change the multiple sclerosis course. Conversely, CDW at any point was associated with worsened disability at year 9. (Source: Neurology and Therapy)
Source: Neurology and Therapy - June 24, 2021 Category: Neurology Source Type: research
Multiple sclerosis and immune system biomarkers: Novel comparison in glatiramer acetate and interferon beta-1a-treated patient groups
Publication date: Available online 15 June 2021Source: Multiple Sclerosis and Related DisordersAuthor(s): Zbysek Pavelek, Michal Novotny, Ondrej Soucek, Jan Krejsek, Lukas Sobisek, Ilona Sejkorova, Jiri Masopust, Kamil Kuca, Martin Valis, Blanka Klimova, Pavel Stourac (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - June 17, 2021 Category: Neurology Source Type: research
